[go: up one dir, main page]

AU2001295760A1 - Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders - Google Patents

Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders

Info

Publication number
AU2001295760A1
AU2001295760A1 AU2001295760A AU9576001A AU2001295760A1 AU 2001295760 A1 AU2001295760 A1 AU 2001295760A1 AU 2001295760 A AU2001295760 A AU 2001295760A AU 9576001 A AU9576001 A AU 9576001A AU 2001295760 A1 AU2001295760 A1 AU 2001295760A1
Authority
AU
Australia
Prior art keywords
resveratrol
treating inflammatory
respiratory disorders
inflammatory respiratory
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295760A
Inventor
Peter John Barnes
Louise Elizabeth Donnelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of AU2001295760A1 publication Critical patent/AU2001295760A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method is provided for treating inflammatory respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The method involves administration, preferably oral or pulmonary administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.
AU2001295760A 2000-10-19 2001-10-19 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders Abandoned AU2001295760A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/694,108 US6878751B1 (en) 2000-10-19 2000-10-19 Administration of resveratrol to treat inflammatory respiratory disorders
US09/694,108 2000-10-19
PCT/GB2001/004672 WO2002032410A2 (en) 2000-10-19 2001-10-19 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders

Publications (1)

Publication Number Publication Date
AU2001295760A1 true AU2001295760A1 (en) 2002-04-29

Family

ID=24787430

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295760A Abandoned AU2001295760A1 (en) 2000-10-19 2001-10-19 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders

Country Status (12)

Country Link
US (1) US6878751B1 (en)
EP (1) EP1326595B1 (en)
AT (1) ATE330589T1 (en)
AU (1) AU2001295760A1 (en)
CA (1) CA2425420C (en)
CY (1) CY1107498T1 (en)
DE (1) DE60121012T2 (en)
DK (1) DK1326595T3 (en)
ES (1) ES2266271T3 (en)
PT (1) PT1326595E (en)
WO (1) WO2002032410A2 (en)
ZA (1) ZA200302727B (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2419164T3 (en) 2001-11-02 2013-08-19 The Regents Of The University Of California Compositions for the prevention and treatment of an inflammatory disease, an autoimmune disease, and transplant rejection
US20070218151A1 (en) * 2002-03-12 2007-09-20 Universidade Do Estado Do Rio De Janeiro Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
DE60216242T2 (en) * 2002-06-06 2007-05-24 Chiesi Farmaceutici S.P.A. Solution of active ingredients in HFA propellants by means of emulsions
KR20050010916A (en) * 2002-06-13 2005-01-28 와이어쓰 홀딩스 코포레이션 Inhibitors of inflammatory gene activity and cholesterol biosynthesis
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004105769A1 (en) * 2003-05-28 2004-12-09 Universite De Liege Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin
KR20060120101A (en) * 2003-10-10 2006-11-24 리스버로직스 코퍼레이션 Treatment of Diseases Associated with EBR-1 Enhancer Element
CA2805795C (en) 2004-01-20 2016-11-08 Brigham Young University Novel sirtuin activating compounds and methods for making the same
EP1753419B1 (en) * 2004-06-21 2014-01-15 University of Mississippi Anticancer and antiprotozoal dihydroartemisinin and dihydroartemisitene dimers with desirable chemical functionalities
WO2006091841A2 (en) * 2005-02-25 2006-08-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
WO2006102407A2 (en) 2005-03-23 2006-09-28 Children's Medical Center Corporation Orthotic device for preventing and/or correcting deformational posterior plagiocephaly
EP1928440A2 (en) * 2005-05-25 2008-06-11 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060293261A1 (en) * 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
AU2006269459B2 (en) * 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20100056606A1 (en) * 2005-10-03 2010-03-04 Isis Pharmaceuticals, Inc. Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha
JP2009519970A (en) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド Process for producing particle-based pharmaceutical dosage forms for oral administration
US20070270366A1 (en) * 2005-12-20 2007-11-22 Karras James G Double stranded nucleic acid molecules targeted to il-4 receptor alpha
CA2633099C (en) * 2005-12-21 2015-04-21 Uti Limited Partnership Treatment of respiratory diseases
WO2007103869A2 (en) * 2006-03-06 2007-09-13 Wyeth Liquid and semi-solid pharmaceutical formulations and processes
FR2898493B1 (en) * 2006-03-16 2008-08-08 Af Consulting COSMETIC, PHARMACEUTICAL, FOOD AND VETERINARY COMPOSITIONS WHOSE ACTION ACTIVATION OF SIRTUIN GENES ENABLES DELAYING THE AGING OF MAMMALS AND ITS NEGATIVE EFFECTS
ES2344920T3 (en) * 2006-03-28 2010-09-09 Epitech Group S.R.L. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PATHOLOGIES CAUSED BY THE GENERAL RESPONSE OF THE IMMUTARY SYSTEM.
WO2008144748A1 (en) * 2007-05-21 2008-11-27 The Uab Research Foundation Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation
US20100210735A1 (en) * 2007-08-06 2010-08-19 University Of Florida Research Foundation, Inc. Modulating the Activity of Nuclear Receptors in Order to Treat Hypoxia-Related Disorders
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
EP2671614A1 (en) * 2007-12-21 2013-12-11 University of Rochester Molecular Targets for Treatment of Inflammation
MX2010007610A (en) 2008-01-11 2010-12-14 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease.
GB0801032D0 (en) * 2008-01-21 2008-02-27 Univ York Immune modulation
EP2259782A4 (en) * 2008-03-03 2013-01-23 Nad Life Pty Ltd PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USING THE SAME FOR TREATING CELLULAR DISORDERS
CN102164941B (en) 2008-04-18 2015-05-27 里亚塔医药公司 Antioxidant inflammation regulator oleanolic acid derivative having saturated C ring
CA2721838C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
ME02751B (en) 2008-04-18 2018-01-20 Reata Pharmaceuticals Inc ANTIOXIDANT AGENTS AS INFLAMMATORY MODULATING SUBSTANCES: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES
NZ588708A (en) * 2008-04-18 2012-09-28 Reata Pharmaceuticals Inc 2-cyano steroid derivatives including an anti-inflammatory pharmacore
US20090307669A1 (en) * 2008-06-06 2009-12-10 Garst Jr Gerald Blaine Memory management for closures
WO2010011782A1 (en) 2008-07-22 2010-01-28 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
ES2362065B1 (en) * 2009-12-15 2012-05-18 Consejo Superior De Investigaciones Cient�?Ficas (Csic) COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY.
KR101819699B1 (en) 2010-04-12 2018-01-17 리아타 파마슈티컬즈, 아이엔씨. Method of treating obesity using antioxidant inflammation modulators
CN101791292A (en) * 2010-04-13 2010-08-04 江庆澜 Application of polygonin atomizing agent as asthma-treating medicine
US20120121730A1 (en) * 2010-10-07 2012-05-17 Trinity Laboratories, Inc. Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm
MX2013006902A (en) 2010-12-17 2013-10-17 Reata Pharmaceuticals Inc Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators.
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
AU2012229244B2 (en) 2011-03-11 2017-05-25 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
CA2869783C (en) 2012-04-27 2022-06-21 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US8865772B2 (en) 2012-07-26 2014-10-21 The William M. Yarbrough Foundation Method for treating skin cancer
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
WO2014040060A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CN105101958B (en) * 2013-01-15 2019-05-17 纽斯尔特科学公司 treat lung conditions
CA2921937C (en) 2013-08-21 2023-10-03 Concordia University Dendrimer-resveratrol complex
US10667627B2 (en) 2015-05-05 2020-06-02 Children's Medical Center Corporation Devices and methods for supporting and containing premature babies and small-for-age infants
MX386256B (en) 2015-09-23 2025-03-18 Reata Pharmaceuticals Inc C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR IL-17 INHIBITION AND OTHER USES.
ES2673942B1 (en) * 2016-11-23 2019-04-09 Consejo Superior Investigacion ACRYLIC COMPOUNDS FOR THE TREATMENT OF EYE PATHOLOGIES
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
MX2022009050A (en) 2020-01-22 2022-10-27 Seelos Therapeutics Inc REDUCTION OF THE SIDE EFFECTS OF NMDA ANTAGONISTS.
EP4019013A1 (en) 2020-12-24 2022-06-29 Bionotus GCV Treatment of pulmonary disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577196A (en) * 1977-06-03 1980-10-22 Ile De France Compositions containing erythromycin and metoclopramide
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
IT1276225B1 (en) 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ALKANOYL L-CARNITINE IN ASSOCIATION WITH RESVERATROL OR ITS DERIVATIVES USEFUL FOR
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US5972995A (en) 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6022901A (en) 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
ES2258337T3 (en) 1998-09-08 2006-08-16 Cornell Research Foundation, Inc. USE OF CYCLLOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF HEAD AND NECK INFLAMMATORY DISEASES.
CA2350396C (en) 1998-12-24 2010-06-29 1333366 Ontario Inc. A composition useful to treat periodontal disease
PE20010540A1 (en) 1999-07-30 2001-05-15 Procter & Gamble COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES
IT1318425B1 (en) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro USE OF RESVERATROL FOR THE TREATMENT OF DESQUAMATIVE ECZEMA, ACNE AND PSORIASIS.

Also Published As

Publication number Publication date
ATE330589T1 (en) 2006-07-15
CA2425420C (en) 2010-10-12
ES2266271T3 (en) 2007-03-01
US6878751B1 (en) 2005-04-12
WO2002032410A2 (en) 2002-04-25
CA2425420A1 (en) 2002-04-25
DK1326595T3 (en) 2006-10-23
DE60121012T2 (en) 2007-01-04
EP1326595A2 (en) 2003-07-16
DE60121012D1 (en) 2006-08-03
ZA200302727B (en) 2004-04-08
WO2002032410A3 (en) 2002-08-01
CY1107498T1 (en) 2013-03-13
EP1326595B1 (en) 2006-06-21
PT1326595E (en) 2006-09-29

Similar Documents

Publication Publication Date Title
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
EP3494995A3 (en) Formoterol superfine formulation
BR0008699A (en) Combinations of formoterol and demometasone furoate for asthma
MY126768A (en) Combinations of formoterol and fluticasone propionate for asthma
IL219785A0 (en) Process for preparing a pharmaceutical composition containing an active ingredient and a micronised carrier/diluent
FI20002215A0 (en) Combination Particles
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
CA2474479A1 (en) Composition for inhalation
DK1341542T3 (en) Indanyl derivatives for the treatment of respiratory diseases
CA2550841A1 (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
NZ513304A (en) Combinations of formoterol and a tiotropium salt
MXPA02011311A (en) Novel composition.
GB0008660D0 (en) The treatment of respiratory diseases
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
HRP20050224B1 (en) COMBINATION OF LOTEPREDNOL ETHOBONATE AND DFHO FOR THE TREATMENT OF AIRCRAFT DISEASES, ALLERGIC DISEASES, ASTHMA AND CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD)
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
JP2008115167A (en) Suppressor for goblet cell hyperplasia of respiratory tract containing tranexamic acid
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
WO2005011616A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
MXPA04007294A (en) Composition for inhalation.
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
BR0308984A (en) Powder formulations suitable for inhalation
IS2576B (en) A synergistic composition comprising roflumilast and (R.R) -formoterol